The future of ACUS is not going to be known until probably the middle of next year. That is a year or more away. There is no way the CFO knows any more about the potential for approval than any of us. There are few if any material facts that are presently not disclosed. The only that I am aware of is what the 6 serious adverse events specifically were. Why this is not being disclosed, I don't know.Think of it this way, DNDN's management never sold shares and were buying shares going into the AC meeting for Provenge. They turned out to be right on March 29. They then sold some prior to the FDA final decision, and were prudent, but no one at DNDN knew or had any inkling better than any of us as to what the FDA was going to do.I've seen multiple small biotechs who spend a fortune putting into place a sales force well before the FDA decision, very confident in approval, only to see the FDA surprise them completely.I think what might be said is that this is not a slam dunk, and no one really knows. If someone had enough insight to confidently know one way or the other one might just stick around and collect as many stock options as possible. On the other hand, the stock options that have vested will remain with Mr. Thero, whether or not he continues to work with ACUS, so he has nothing to lose.All in all, means less than we might think, other than, it probably puts the exclamation point on the fact that the decision is expected to go either way, and no one is strongly leaning that this is a slam dunk decision. Tinker
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar<